Ascidian Therapeutics

Ascidian Therapeutics

  • Founded: 2020
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: ocular
  • Drug types: OPH, NEU
  • Lead product: ABCA4
  • Product link:
  • Funding: $50M A Oct 2022
  • Investors: ATP

job board

Short description:

Mutated exon replacement

Drug notes:

7 add'l RD programs

Long description:

Ascidian Therapeutics is creating gene therapies that replace exons via selective splicing of pre-mRNA. The technology is called RNA exon editing. A designer RNA is used to replace mutated, disease-causing exons within pre-mRNA. Multiple continuous exons can be replaced. This gene therapy approach allows editing large portions of RNA (rather than just single base changes), avoids the risks of direct DNA editing, and does not alter endogenous gene expression levels. The company is named Ascidian, because their technology is based on a biological process that naturally occurs in ocean creatures called ascidians (also known as sea squirts). Ascidians use unique mechanisms of RNA splicing to re-engineer their transcriptome in developing from larvae to adults.


Ascidian Therapeutics
Senior Associate Scientist - Molecular Biology & A...
Boston, MA|66 days ago
Ascidian Therapeutics
Senior Alliance Lead
Boston, MA|68 days ago
Ascidian Therapeutics
Head of Data Science
Boston, MA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy